Special Issue

Recent Advances and Breakthroughs in Cancer Treatment and Bone Metastasis

Message from the Guest Editor

Bone metastasis is a common complication in advanced stages of various cancers, including breast, lung, prostate, kidney, and thyroid. Bone metastasis often leads to significant complications\(\)which significantly impact the quality of life of patients. Managing bone metastasis implies a multidisciplinary approach to enhance patients' quality of life. Surgery, radiation, and chemotherapy are the common approaches used to treat cancer patients. However, in recent years, research advancements emphasizing the development of targeted therapies, precision medicine, immunotherapy, and innovative approaches have shifted the cancer treatment landscape, leading to improved patient outcomes. In this Special Issue, we cover the latest advancements and breakthroughs in cancer treatment, specifically focusing on their implications for treating bone metastases. This Special Issue incorporates molecular mechanisms underlying bone metastasis, the complex role of the tumor microenvironment, and emerging therapeutic strategies to target metastatic lesions within the bone microenvironment. I look forward to receiving your contributions.

Guest Editor

Dr. Jawed A. Siddiqui

Department of Biochemistry and Molecular Biology, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA

Deadline for manuscript submissions

closed (30 September 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/194385

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

